Sep 30, 2019
Lund, Sweden September 30, 2019. Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that the Company’s registered share capital and number of outstanding shares and votes have increased during the month of September 2019.
As previously announced on 2 September 2019, Hansa Biopharma’s board of directors resolved to issue 715,910 class C shares, by virtue of the authorization by the general meeting held on 22 May 2019 as part of the implementation of the incentive programme LTIP 2019, which was adopted by the annual general meeting held on 22 May 2019. All class C shares are owned by the Company.
As of today, the total number of registered and outstanding shares of Hansa Biopharma amounts to 41,447,564, whereof 40,026,107 are ordinary shares and 1,421,457 are class C shares. As of today, the number of votes in Hansa Biopharma amounts to 40,168,252.7, and the registered share capital amounts to SEK 41,447,564.